Redmile Group LLC lowered its holdings in Repare Therapeutics Inc. (NASDAQ:RPTX – Free Report) by 6.2% in the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 2,016,302 shares of the company’s stock after selling 132,446 shares during the period. Redmile Group LLC’s holdings in Repare Therapeutics were worth $9,497,000 as of its most recent SEC filing.
Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. BVF Inc. IL lifted its holdings in shares of Repare Therapeutics by 24.6% during the 4th quarter. BVF Inc. IL now owns 10,333,600 shares of the company’s stock worth $75,435,000 after acquiring an additional 2,041,612 shares during the period. Jump Financial LLC acquired a new position in Repare Therapeutics during the fourth quarter worth approximately $289,000. Acadian Asset Management LLC increased its position in Repare Therapeutics by 53.5% during the first quarter. Acadian Asset Management LLC now owns 133,893 shares of the company’s stock worth $625,000 after purchasing an additional 46,648 shares during the last quarter. SRS Capital Advisors Inc. raised its stake in Repare Therapeutics by 100.0% during the fourth quarter. SRS Capital Advisors Inc. now owns 10,000 shares of the company’s stock worth $73,000 after purchasing an additional 5,000 shares during the period. Finally, Vontobel Holding Ltd. acquired a new position in Repare Therapeutics in the fourth quarter valued at $110,000. Hedge funds and other institutional investors own 85.09% of the company’s stock.
Repare Therapeutics Stock Performance
Shares of NASDAQ:RPTX traded up $0.05 during trading on Monday, hitting $3.99. The company’s stock had a trading volume of 136,818 shares, compared to its average volume of 192,795. The stock’s 50-day moving average price is $3.57 and its two-hundred day moving average price is $4.64. Repare Therapeutics Inc. has a fifty-two week low of $2.98 and a fifty-two week high of $13.85. The company has a market capitalization of $169.36 million, a PE ratio of -3.63 and a beta of 0.73.
Analyst Upgrades and Downgrades
Several equities research analysts have commented on RPTX shares. Bloom Burton upgraded Repare Therapeutics from an “accumulate” rating to a “buy” rating in a research note on Friday, April 19th. HC Wainwright reiterated a “buy” rating and issued a $10.00 target price on shares of Repare Therapeutics in a research note on Wednesday, June 5th.
Get Our Latest Stock Report on RPTX
Repare Therapeutics Profile
Repare Therapeutics Inc, a clinical-stage precision oncology company, engages in the discovery and development of therapeutics by using its synthetic lethality approach in Canada and the United States. It uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform, to discover, validate, and build a pipeline of SL-based therapeutics that focuses on genomic instability, including DNA damage repair.
See Also
- Five stocks we like better than Repare Therapeutics
- What Investors Need to Know to Beat the Market
- Survey: Top 175 Fittest Retirement Locations in America
- How to Invest in Biotech Stocks
- Kimberly-Clark Stock Dips and a Buying Opportunity Emerges
- Which Wall Street Analysts are the Most Accurate?
- Leading Gold Stock Shines With Q2 2024 Earnings Release
Want to see what other hedge funds are holding RPTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Repare Therapeutics Inc. (NASDAQ:RPTX – Free Report).
Receive News & Ratings for Repare Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repare Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.